Basic Information
| LncRNA/CircRNA Name | SCARNA2 |
| Synonyms | HBII-382, mgU2-25/61 |
| Region | GRCh38_1:109100193-109100619 |
| Ensemble | ENSG00000278249 |
| Refseq | NR_003023 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Luciferase reporter assay, other |
| Sample | CRC tissues and cell lines LoVo, HCT 116, LSI74T, COLO 205, HT-29, and SW480 |
| Expression Pattern | up-regulated |
| Function Description | SCARNA2 overexpression significantly promoted chemoresistance in CRC cells, and downregulation of SCARNA2 obviously inhibited chemoresistance in vitro. SCARNA2 promotes chemotherapy resistance via competitively binding miR-342-3p to facilitate epidermal growth factor receptor (EGFR) and B-cell lymphoma 2 (BCL2) expression in CRC cells.? |
| Pubmed ID | 30443961 |
| Year | 2019 |
| Title | The lncRNA SCARNA2 mediates colorectal cancer chemoresistance through a conserved microRNA-342-3p target sequence. |
External Links
| Links for SCARNA2 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |